HC Wainwright Comments on Cytokinetics Q1 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Cytokinetics in a report released on Wednesday, February 25th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($1.57) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $136.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q2 2026 earnings at ($1.61) EPS and Q4 2026 earnings at ($1.89) EPS.

Other analysts also recently issued reports about the company. Wall Street Zen downgraded Cytokinetics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Leerink Partners set a $83.00 target price on shares of Cytokinetics in a research note on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Bank of America reiterated a “neutral” rating on shares of Cytokinetics in a report on Wednesday. Finally, Barclays started coverage on shares of Cytokinetics in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price objective on the stock. Sixteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.78.

Cytokinetics Stock Performance

Shares of Cytokinetics stock opened at $62.89 on Thursday. The stock has a market cap of $7.69 billion, a price-to-earnings ratio of -9.63 and a beta of 0.54. The stock has a 50 day moving average price of $64.21 and a 200-day moving average price of $58.35. Cytokinetics has a one year low of $29.31 and a one year high of $70.98.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. During the same quarter in the prior year, the firm earned ($1.26) earnings per share. Cytokinetics’s revenue was up 4.9% compared to the same quarter last year.

Hedge Funds Weigh In On Cytokinetics

Several institutional investors have recently made changes to their positions in CYTK. Lisanti Capital Growth LLC bought a new position in Cytokinetics in the third quarter worth about $2,697,000. Sanders Morris Harris LLC bought a new stake in shares of Cytokinetics in the 3rd quarter valued at about $1,182,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Cytokinetics in the 3rd quarter worth approximately $1,359,000. Moody Aldrich Partners LLC purchased a new position in shares of Cytokinetics in the 3rd quarter worth approximately $4,532,000. Finally, Norges Bank bought a new position in shares of Cytokinetics during the 2nd quarter worth approximately $39,122,000.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, Director Wendell Wierenga sold 20,000 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the transaction, the director directly owned 32,444 shares in the company, valued at $2,145,846.16. This represents a 38.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew Callos sold 15,000 shares of Cytokinetics stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $61.93, for a total transaction of $928,950.00. Following the sale, the executive vice president directly owned 50,440 shares of the company’s stock, valued at $3,123,749.20. This represents a 22.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 151,385 shares of company stock valued at $9,817,158 in the last three months. Company insiders own 2.70% of the company’s stock.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in U.S., China and Europe and U.S. launch is already underway; company reiterated 2026 catalysts (including ACACIA‑HCM topline in Q2) and disclosed substantial cash reserves. This is a material commercial and pipeline positive for future revenue. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised price targets and kept bullish ratings (Citizens JMP to $96 market‑outperform; Needham to $85 buy), signaling continued analyst conviction and upside vs. the current price. Benzinga coverage
• Positive Sentiment: Company highlighted a strong cash position (~$1.2B) to fund commercialization and upcoming trials — a balance‑sheet cushion that supports execution into 2026 catalysts. Zacks: CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
• Neutral Sentiment: Revenue beat estimates ($17.7M reported vs. ~$8M consensus), showing commercial pickup or other revenue sources, but revenue alone did not offset rising expenses this quarter. MarketBeat: Earnings details
• Neutral Sentiment: Full earnings call and transcripts are available for investors wanting details on expense drivers, launch timing and trial expectations. Seeking Alpha: Q4 2025 earnings call transcript InsiderMonkey transcript
• Negative Sentiment: EPS missed marginally ($‑1.50 vs. $‑1.48 expected) and the loss widened year‑over‑year as expenses rose, which likely triggered near‑term selling despite the revenue beat and approvals. Zacks: Q4 Loss, Beats Revenue Estimates

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.